ArticleBritish journal of haematology2026
Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
While plasma-derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor-like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet-derived 3-α (REG3α) retain their utility in the mismatched unrelated donor (MMUD) setting. We assessed their prognostic ability in 53 subjects who received MMUD HSCT from 2016 to 2023 with Day 14 or Day-30 post-HSCT samples in batch using sequential enzyme-linked immunosorbent assay. Elevated Day-30 biomarker concentrations held more prognostic value than Day 14 concentrations. Day-30 CXCL9 value showed association for overall survival (OS) with a hazard ratio of 5.86 (95% confidence interval [CI] 1.21, 28.3, p = 0.03). When stratified by high or lower threshold concentrations, Day-30 concentration revealed differences in 2-year OS for IL1RL1 (p = 0.027), CXCL9 (p = 0.011) and REG3α (p = 0.044). Day-30 area under the curve (AUCt) performance for risk of death by 2 years was 0.86 (95% CI 0.71, 1) for the combination of CXCL9 and IL1RL1, which was superior to any individual biomarker value. In this pilot analysis, Day-30 biomarkers are discriminative for OS at 2 years post-HSCT and may be able to guide future pre-emptive intervention and monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.